Close Menu

NEW YORK – Suzhou, China-headquartered Ascentage Pharma said on Tuesday that regulators in China have given it permission to start a Phase IIa trial of the MDM2-p53 inhibitor, dubbed APG-115, for the treatment of relapsed or refractory T-cell prolymphocytic leukemia.

T-PLL is a rare and aggressive leukemia characterized by a mutation in ATM located in the 11q22-23 region in the vast majority of cases. Patients with this disease tend not to respond to available chemotherapies and to live between six and nine months on average after diagnosis.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.